0001558370-22-001615.txt : 20220222 0001558370-22-001615.hdr.sgml : 20220222 20220222164524 ACCESSION NUMBER: 0001558370-22-001615 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220218 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 22658892 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 sgtx-20220218x8k.htm 8-K
0001821323false00018213232022-02-182022-02-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 18, 2022

SIGILON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39746

47-4005543

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

100 Binney Street, Suite 600, Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 336-7540

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Name of each exchange

Title of each class

    

Symbol(s)

    

on which registered

Common Stock, $0.001 par value per share

SGTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 18, 2022, the Board of Directors of Sigilon Therapeutics, Inc. (the “Company”) appointed Josias Fantato De Pontes as the Company’s Acting Chief Financial Officer and Treasurer. Upon his appointment, Mr. Pontes replaced Dr. Rogerio Vivaldi, M.D., as the Company’s principal financial officer. Mr. Pontes will continue to serve as the Company’s principal accounting officer.

Mr. Pontes, age 55, previously served as the Company's Vice President, Head of Finance since November 2019. Prior to joining the Company, Mr. Pontes was Senior Director, Financial Planning and Analysis at Zafgen, Inc., a biotechnology company, from December 2017 to August 2019.  From 2016 to 2018, Mr. Pontes served as Senior Director, Accounting Reporting and Consolidation and Financial Planning and Analysis at Juniper Pharmaceuticals, Inc.  Mr. Pontes also worked in various finance roles of increasing responsibility at Genzyme, most recently serving as the Senior Director of Finance and Controller of the Rare Diseases business unit. He holds an MBA from Ohio University and a B.A. in Accounting from the FECAP University in Sao Paulo, Brazil.

There is no family relationship between Mr. Pontes and any director or executive officer of the Company and Mr. Pontes has no direct or indirect material interest required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On February 22, 2022, the Company announced in a press release that Qing Sarah Yuan, Ph.D. is expected to join the Company as its Chief Technical Operations Officer, effective March 7, 2022. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information in Item 7.01 of this Form 8 K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release Issued by Sigilon Therapeutics, Inc. on February 22, 2022

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGILON THERAPEUTICS, INC.

By:

/s/ Rogerio Vivaldi Coelho, M.D.

Rogerio Vivaldi Coelho, M.D.

President and Chief Executive Officer

Date: February 22, 2022

EX-99.1 2 sgtx-20220218xex99d1.htm EX-99.1

Exhibit 99.1

A picture containing logo

Description automatically generated

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

Cambridge, MA—February 22, 2022—Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022. Dr. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biopharmaceutical companies.

“We are delighted to welcome Sarah, a biopharma veteran, to the Sigilon team,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “Sarah has an impressive track record of spearheading innovative manufacturing processes and leading CMC activities for assets ranging from preclinical to commercial-stage. We believe Sarah’s insights will have an immediate impact as we continue to optimize our platform and work toward achieving our near-term milestones for our programs in MPS-1 and diabetes.”

Prior to joining Sigilon Therapeutics, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio. At 2seventy bio, she was instrumental in getting three cell therapy products approved, in addition to advancing a preclinical product through IND clearance. Previously, Dr. Yuan led the External Manufacturing Organization for the Rare Blood Disorders Franchise at Sanofi. She also served as the Head of Technical Development and Manufacturing Sciences at Bioverativ, prior to its acquisition by Sanofi. At Bioverativ, she built and developed high functioning teams responsible for overseeing external manufacturing operations, developing and executing CMC strategies, delivering manufacturing processes, analytical methods and driving life cycle management initiatives for all clinical and commercial products. Earlier in her career, Dr. Yuan held various roles with increasing responsibilities in Biogen’s Manufacturing Sciences department, led Process Development at Agenus, and spent several years developing novel resins and membranes at Millipore. Sarah holds a Ph.D. in Chemical Engineering from University of Wisconsin, Madison, and a B.S. in Chemical Engineering from University of California at Berkeley.

“I am pleased to be joining the Sigilon team at such an important stage of its development,” commented Dr. Yuan. “I have dedicated a large part of my career to advancing novel platform technologies, and I look forward to working with this highly talented team to recognize the potential of Sigilon’s Shielded Living Therapeutics™ platform and novel allogeneic cell therapies.”

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from


immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters, including the potential impact on our platform technology and programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that favorable preclinical results are not predictive of clinical trial results, the FDA or other regulators may request additional preclinical studies or clinical trials beyond those that we currently anticipate, and the risks identified under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2021 and in any subsequent filings with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

SOURCE: Sigilon Therapeutics, Inc.

Investor Contact
Robert Windsor, Jr., J.D.

VP, Head of Investor Relations

Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837

Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

##


GRAPHIC 3 sgtx-20220218xex99d1001.jpg GRAPHIC begin 644 sgtx-20220218xex99d1001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#WZBBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I P M/0BJ.L3RP:<[PYW=,CL/6N5L;B:.^B9';+. >>O->7B\R6'K1I.-[G12P[J0 M:_%*XN5 MEL8 6%N5+''0MG_"@#O+'5K#42PL[N*8KU"-R*O5X'XN+FVU MZR>U)\WS5&!W!//Z5[!XR_Y%'4O^N7]10!R'_"U)_P#H&1_]_#7I4;^9$CXQ MN4'%?.5?1=O_ ,>L7^XO\J8%%_M_]L+M_P"/3'/Y?SS5U+F&24Q)(I=>H!J0 MC(KGM.T>ZMM36:0C8I)R#R>U>=4E5H32@N92>OD;1Y9IW=K'14M<_JFMS6UX MT$*@!,9)[\9K2AOQ)IGVPJ1\I8CZ5=/'49SE!/6.XG1E%*3ZEVJ6I:@NGP!R MNYF.%%SDN?9 MD%EK27\WV:>%5WC YR#[5?ATRT@E$D<*ANQK+TK1)8+D3W&!LY4 UT J\!3J MU*?-B8^\*LXQE:F] %+24M>H 7>MZKJ4X>>\GDP%,BU/4["XWI=7$,H]6(-.P'T%5#5=)L M]9LS;7D0=#R#T(]P:Y7P-XJU#69'L[R%I/+7/VA1@?1J?\1=3OM,LK%[*YD@ M9Y&#%#C(P*0&QI'A'2-%NC:1@,[%L?3-;U>0^$O$>L7GB>QM[G4)Y(7 M@KB)=3OIY6 MEDNYF=SDDN>318#Z&HKP73?$NKZ5('MKR3;G)1SN4\8Y!K>\0>.;N_@L9M.N M9K23:PN(D; W<<_2G8#URJ.J:5::Q9M:WD0>,_F#Z@UQ/P[UG4=3U"\2]O)9 MU2(%0[9PZ9IMG)97,D#O,58H<9&*0&II/@_2-&N_M-K"WFXP&=B MV/IFG>,O^10U+_KE_45YYX8\2:S=^)K""XU&XDB>7#(S9!H?C+_D4-2_Z MY?U% 'AE?1=M_P >L/\ N+_*OG2OHNW_ ./6+_<7^5-@2TAKFO%/C"V\.JL* M*)[UQD19X4>K?X5Y;J/BG6=49OM%[)L)!\M#M4$>PI6 ]COM%AOI_.+,C'[V M.]7HK>.&W$"*/+ QBOGW[==@C%S-_P!]FNDT7Q]JNFS(MU*;NWS\RR'Y@/8U MA#"TH3P3.=G;Z5L(H10JC"@8 JGI.JVVLZ>EY M:MF-N"#U4^AK)\+-4UFX=GN'BAW92%#@**Z+$'NE%? M/4.JW]M,LL-Y.DB]"'.17IO@?QC)K#G3M0(^UJI9).!Y@';ZTK =Q1110 5X MCX[+'QE?[B2 4 SZ;%KVZN/\8>#1K[+>6KB.\1=I#=''^- '/?#N]T2UBG2[ M:*.]=^&EZ%<9P/3G^E=SJ>C:7X@L3%*L3!N4ECQN!]0:\?O/"VLV+8EL)3GN M@S5&"^O]/D!AN)X7' PQ&*=A'N^E:5::/8I:6D85%')[L?4UQWQ4_P"0?IW_ M %U?^0IO@OQM+?7*:;J3;IGXBE ZGT-.^*G_ "#]._ZZO_(4#..\$_\ (X:= M_OG_ -!->C?$#4WT[PT\<3[9;EO*ZX.W^+'Z#\:\Y\$_\CCIW^^?_0376_%7 M_CVTSTWR?R6@#SNPL9M2OX;.W7=+,VU?\?RKV31O!>D:5;HKVR7%P.3+*,G/ MMZ5YQX!:)?&-GYG4APA_VMI_IFO:Z&!BZCX5T?4HG6:QB5V&/,0;6'XUXYX@ MT:30=8ELI"64?-&Y_B0]#_GTKWVO*/B@T1UNU51^]$'SGVSQ_6A 2_"S_D)W MW_7$?^A"M7XI_P#((L?^NY_]!-97PL_Y"=]_UQ'_ *$*U?BG_P @BQ_Z[G_T M$T=0.'\'_P#(W:9_UV'\C7K'C+_D4-2_ZY?U%>3^#_\ D;M,_P"NP_D:]8\9 M?\BAJ7_7+^HH8'AE?0K7"6FDFYDR4A@\QL=F M.?TS0P1XKJ5_-JFHSWMPQ:25BWT'8?2O1?!W@>S.G0ZCJD7G2S+O2)ONJI'& M1W)!S^5>7U]&Q%6B0H04*C;CIBA@4)O#^DW$*PRZ?;LBCY1L'%>6>-/"B^'[ MB.>UW&SF.!N.2C>GY5[+7)?$8PCPI)YFW>94\O/7.>E:5:QQK:QRS!IKHJ\X\6^!+R\OI=0L)#,TIR\;GD'V]J .UTW M6]/U6T6>WN$*L,E68 K[$5R/Q%72!I 91#]N+KY>S&<=^E<)_8.N0$@6-TG/ M.T$5)#X8UZ]E5/L,^X]&DX'YFF(C\,)+)XFT]83A_.&#Z5W?Q4_Y!^G?]=7_ M )"KO@_P6-$?[;>,'NR,*!T0?XTGQ"TB]U:RLDLH3*R2,6 [#% S@O!/_(X: M?_OG_P!!->F^-](DU?PY*D*[IX6$J #DXZC\C^E<3X4\+ZO8^)K*YN+1DB1B M68]N#7K5#!'SI;SRV=W'/"Q26)PRGT(KU;2/B)IES9K_ &@QM[A0-_&0QYZ? ME^M5O$WP]CO9'N]+(BF8EGB/W6^GXUPUQX3URVF\M]/E8@9R@R/SH ])U#X@ MZ-:VSM;R&XEY 11CG'\J\IU74[C5]1EO;ELR2'IV4=@*V--\"ZW?LI:W^SQD MD%I>,?A4?C#18-!U2WLH"6 ME9V/\3$MD_I0!O?"S_D*7W_7$?\ H0K5^*?_ M ""+'_KN?_036;\+(F-Y?S8^41A,^Y.?Z5O?$'2;W5=-M([*$RNDQ9@.PQ1U M \[\'_\ (W:9_P!=A_(UZQXR_P"10U+_ *Y?U%>?^&?"^L6?B2PN)[1DBCER MS'L,5Z-XHM9KWPU?6UNA>62/"J._(H8'@U?0Q@2ZTO[/)]R6'8V/0K@UXM_P MANN_\^+U[= I6WC4C!"@$?A0P/ -6TV;2=3GLIUP\;$ ^H[&N[\(>.[>WL4T M_57V>2H6*7&%;7Q%;KO/E7*?*-%M8&E>_A*KV5LFO+?&/BG_A(KJ)(%9+2'[H/5F/^_T6 X)SRQ_"@!WPYT9KW6O[0D7]Q:\@GNYZ?EUK ML/B+_P BC-_UU3^=;^EZ9:Z38QVEI&$C4?B3ZFLGQO87.I>&I+:TC,DID0A1 M[&D!Y;X/_P"1NTS_ *[?T->ZUY'X9\+ZQ9>)+"YGLV2*.3+,>W!KUL4V!SGC MS_D4+S_@/_H0KR+0O^1ATW_KZB_]#%>R>,+*?4/#-U;6T9DF;;A1WYKS72/" M6M6^M6,TEDRQQW$;L?0!@ST4E+2 **** $(S12U6M-0M+YIEM;B.4PML MD"'.T^AH LT444 %,ED2&)Y9'"H@+,QZ "GUD^(M*N-9T>6RM[HV[N1EL<,/ M0^U '/V/Q$T^XU>XMI_W5MNQ!.>A'3GT]:[&&YAN%#0RI(I (*L#Q7@^I^'= M4TB79=VDBC)PZC*MZX(JG!>7=KGR+B6+/78Y%.PCWV_U2RTVVDGNKA(T09() MY_*O#_$>L-KFMSWN"J-A8U)^ZHZ?X_C5"26YNY:K/ M'/?1O;V(^8EAAI/8#^M SJ_AIISVNAS7;A@;J3*@_P!U>_ZG\J[>HH(([6". M"% D4:A54= !4M( HHHH **** "BBB@!!]*6BB@ HH)QR>E(&##(((]J %HH MHH **** "BBB@ K UKQ ^EZSI-BD*2+?2E&8MC9RH_K6^1D8]:\M\0^&TL?$ M&AVHOKJ074Q4N[DE/F7IZ=: /400>AS7%> B!>>(,G_E]/\ -JZ#1=#315F5 M;JXN/-(.9F+8QZ?G7">'-(N]8U?6(1>26]BMVS2^4<,[;C@9_.@#U ,#T(I: MX"^MKCPAK^GW$%[<365U)Y,D4SER/IFNF\3:P="T*:\50T@PD8/3<>E &QN M/449R*X+3]$AO+0W6K:_(;N=<[8KC:L9/3H>:L>%]0N+3Q)=Z!+?&^ACB$D$ MQ.<#C@G\1^M '9L%(VM@@C!![U4_LO32?^/&T)_ZXK_A7)>-9+Z#Q%HWV"X> M.:XW0CD[1GC<1[;L_A6YHOAIM(O7NGU*YNG=&1EE/')!R!GV_6@#433[""02 M1V=M&XZ,L2@C\:L@@]"*YG6]$^WZLEQ>:U);6@4;($?82?XN] &_N7U'YT9S7"V_AZTFM#)? M>(IVO)1N+)<;0A/H,U8\(:I7*W+6PWP3!L[T]S^(H [+(SC/-+T% M<;JD\J_%#1H5E<1-;,60,=I.).H_ 5T'B!V3PWJ;HQ5EM)2"#@@[30!HY&,Y MK!L?$#W?BS4-':%%CM8PXD#-]4TXWUTJP1!A*LAWM]WJ?QH ]'U*U-_IMQ:I,T33(5$B]5SWJ MGX;3^S?#LELDTDGE0MB1S\QZGK57P;(\OA M.Q>1V=RARS')/)H W20.IH# ]"#7!(;[QIK=VJWDMKIEF_EXB.&=A6K#X4N+ M#5H+JPU:Y6 '][%,Q?R6>GRJ7EE3 MCYLGC/Y?G5O3_#_V?68;S3-I]ZNVEC;6$(AM8(X8\YVH,4 0K:PRG:FS)Y_+!_&J/BHZ M)%?V%OI-M$"DZF::+D#T7/YG\*]$OM#TW4G\R\LHI9,8W%>?SIJZ!I*VRVXT M^#R0_F!=O&[IF@#(^(?_ ")UQ_UTC_\ 0A2^&O$MG-I5M;7NQ<9JV0""" 0>HH X73K?P7?:,JH\Q7;!4XY&*T?"_]@7%]=2Z M/:%#!^[,VT[7!]#^%:4WA?19YC+)IT!VD"?^10 MT_\ W#_,UL0V=O;V8M(H52W *B,#C![4ZVMH;2!(+>)8XD^ZBC@4 <)X?OH_ M#&OZEINI_N1;%*WW6S[_C742^)M*CU&"Q6Z66:8X C^;'UQ5V^TNRU)56 M\M8YPO3>N<5#9:#I>G2"2TLHHI!QO"\T 4-:U+07OXM*U9$+,-ZF5?E!Z#FN M0O;;3M)\5:0OA^ZVLFR^;:64,4@&-X7G'UH T12TE+0 4444 %%%% !1110 4444 %%%% !1110 M!! EX-101.SCH 4 sgtx-20220218.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sgtx-20220218_lab.xml EX-101.LAB EX-101.PRE 6 sgtx-20220218_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 18, 2022
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Feb. 18, 2022
Entity File Number 001-39746
Entity Registrant Name SIGILON THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-4005543
Entity Address, Address Line One 100 Binney Street
Entity Address, Adress Line Two Suite 600
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 336-7540
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SGTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001821323
Amendment Flag false
XML 8 sgtx-20220218x8k_htm.xml IDEA: XBRL DOCUMENT 0001821323 2022-02-18 2022-02-18 0001821323 false 8-K 2022-02-18 SIGILON THERAPEUTICS, INC. DE 001-39746 47-4005543 100 Binney Street Suite 600 Cambridge MA 02142 617 336-7540 false false false false Common Stock, $0.001 par value per share SGTX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.sigilon.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sgtx-20220218x8k.htm sgtx-20220218.xsd sgtx-20220218_lab.xml sgtx-20220218_pre.xml sgtx-20220218xex99d1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgtx-20220218x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sgtx-20220218x8k.htm" ] }, "labelLink": { "local": [ "sgtx-20220218_lab.xml" ] }, "presentationLink": { "local": [ "sgtx-20220218_pre.xml" ] }, "schema": { "local": [ "sgtx-20220218.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgtx", "nsuri": "http://www.sigilon.com/20220218", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20220218x8k.htm", "contextRef": "Duration_2_18_2022_To_2_18_2022_XlibfM_FxkySWS6oDB33tA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20220218x8k.htm", "contextRef": "Duration_2_18_2022_To_2_18_2022_XlibfM_FxkySWS6oDB33tA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001558370-22-001615-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-001615-xbrl.zip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end